Literature DB >> 6120479

Effect of lithium on circadian neurotransmitter receptor rhythms.

M S Kafka, A Wirz-Justice, D Naber, P J Marangos, T L O'Donohue, T A Wehr.   

Abstract

Chronic lithium administration significantly changes characteristics of the circadian rhythms in rat brain alpha- and beta-adrenergic, muscarinic acetylcholine, dopamine, opiate, and benzodiazepine receptors. There are changes in the timing of the peak number of receptors (phase-position), in the amplitude of the rhythms, and in the 24-hour mean number of receptors. The circadian rhythm in the number of forebrain alpha- and beta-adrenergic and benzodiazepine receptors is abolished. The phase-position of forebrain acetylcholine and opiate receptors and striatal benzodiazepine receptors is delayed. As the rhythms of the dopamine receptor number and alpha-melanocyte-stimulating hormone secretion become bimodal, their phase positions are difficult to evaluate. The mean number of forebrain alpha- and beta-adrenergic, acetylcholine, opiate, and striatal benzodiazepine receptors increases. The mean number of forebrain benzodiazepine and striatal dopamine receptors and the mean concentration of alpha-melanocyte-stimulating hormone decreases. Lithium has profound effects on each of the receptor rhythms measured. Slowing and altering circadian rhythms may contribute to the therapeutic effects of chronic lithium treatment in affective disorders.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6120479     DOI: 10.1159/000117876

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  4 in total

1.  Circadian variation in rat brain AP-1 DNA binding activity after cholinergic stimulation: modulation by lithium.

Authors:  M B Williams; R S Jope
Journal:  Psychopharmacology (Berl)       Date:  1995-12       Impact factor: 4.530

2.  Effect of lithium treatment on the GH-clonidine test in affective disorders.

Authors:  F Brambilla; M Catalano; A Lucca; E Smeraldi
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  Dihydroergotamine, but not naloxone, counteracts lithium as an inhibitor of glucose-induced insulin release in isolated rat islets in vitro.

Authors:  T Fontela; O Garcia Hermida; J Gómez-Acebo
Journal:  Diabetologia       Date:  1987-03       Impact factor: 10.122

4.  Seasonality and sleep: a clinical study on euthymic mood disorder patients.

Authors:  Chiara Brambilla; Chiara Gavinelli; Dario Delmonte; Mara Cigala Fulgosi; Barbara Barbini; Cristina Colombo; Enrico Smeraldi
Journal:  Depress Res Treat       Date:  2011-12-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.